Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy (Q35938862)

11 August 2017

1 reference

title

Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy (English)

1 reference

11 August 2017

cardiovascular disease

1 reference

Ambroisine ML

1

1 reference

11 August 2017

Milliez P

2

1 reference

11 August 2017

Nehme J

3

1 reference

11 August 2017

Pasquier AL

4

1 reference

11 August 2017

De Angelis N

5

1 reference

11 August 2017

Mansier P

6

1 reference

11 August 2017

Swynghedauw B

7

1 reference

11 August 2017

Delcayre C

8

1 reference

11 August 2017

1 September 2004

1 reference

11 August 2017

Diabetes and Metabolism

1 reference

11 August 2017

30

1 reference

11 August 2017

4

1 reference

11 August 2017

311-318

1 reference

Aldosterone and spironolactone in heart failure

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Multiple aspects of mineralocorticoid selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Increase in plasma aldosterone during prolonged captopril treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Efficacy and tolerance of spironolactone in essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

The 45-year story of the development of an anti-aldosterone more specific than spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Cardiovascular complications in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone antagonist improves diastolic function in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone in chronic kidney and cardiac disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Effect of aldosterone on vascular angiotensin II receptors in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone induces a vascular inflammatory phenotype in the rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone-induced inflammation in the rat heart : role of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Spironolactone improves angiotensin-induced vascular changes and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Molecular mechanisms of myocardial remodeling. The role of aldosterone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone production is activated in failing ventricle in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone: direct effects on and production by the heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970122-2

7 January 2021

10.1016/S1262-3636(07)70122-2

Identifiers

DOI

1 reference

11 August 2017

1 reference